| Trade Names: | |
| Synonyms: | |
| Status: | Approved (2006) |
| Entry Type: | Small molecule |
| Molecule Category: | Parent |
| ATC: | N07BA03 |
| UNII: | W6HS99O8ZO |
Structure
| InChI Key | JQSHBVHOMNKWFT-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
Physicochemical Descriptors
| Property Name | Value | |
|---|---|---|
| Molecular Formula | C13H13N3 | |
| Molecular Weight | 211.27 | |
| AlogP | 1.8 | |
| Hydrogen Bond Acceptor | 3.0 | |
| Hydrogen Bond Donor | 1.0 | |
| Number of Rotational Bond | 0.0 | |
| Polar Surface Area | 37.81 | |
| Molecular species | BASE | |
| Aromatic Rings | 2.0 | |
| Heavy Atoms | 16.0 |
Pharmacology
| Action | Mechanism of Action | Reference | |
|---|---|---|---|
| PARTIAL AGONIST | Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | FDA |
| Primary Target | |
|---|---|
| nicotinic acetylcholine receptor α4 subunit |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | ||
|---|---|---|---|---|---|---|---|
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor alpha subunit
|
0-1400 | 39-50000 | - | 0-3540 | 38-38 | ||
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor beta subunit
|
0-1400 | 39-50000 | - | 0-3540 | 38-38 | ||
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor delta subunit
|
- | - | - | 8200 | - | ||
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor gamma subunit
|
- | - | - | 8200 | - | ||
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 1 |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference | ||
|---|---|---|---|---|---|
| Tobacco Use Disorder | 4 | D014029 | ClinicalTrials | ||
| Neoplasms | 3 | D009369 | ClinicalTrials | ||
| Schizophrenia | 3 | D012559 | ClinicalTrials | ||
| Lung Neoplasms | 3 | D008175 | ClinicalTrials | ||
| Lung Neoplasms | 3 | D008175 | ClinicalTrials | ||
| Alcoholism | 3 | D000437 | ClinicalTrials | ||
| Smoking Cessation | 3 | D016540 | ClinicalTrials | ||
| Acute Coronary Syndrome | 3 | D054058 | ClinicalTrials | ||
| Substance-Related Disorders | 2 | D019966 | ClinicalTrials | ||
| Substance-Related Disorders | 2 | D019966 | ClinicalTrials | ||
| Alcohol Drinking | 2 | D000428 | ClinicalTrials | ||
| Amphetamine-Related Disorders | 2 | D019969 | ClinicalTrials | ||
| Psychotic Disorders | 2 | D011618 | ClinicalTrials | ||
| Alzheimer Disease | 2 | D000544 | ClinicalTrials | ||
| Friedreich Ataxia | 2 | D005621 | ClinicalTrials | ||
| Machado-Joseph Disease | 2 | D017827 | ClinicalTrials | ||
| Cocaine-Related Disorders | 2 | D019970 | ClinicalTrials | ||
| Parkinson Disease | 2 | D010300 | ClinicalTrials | ||
| Marijuana Abuse | 2 | D002189 | ClinicalTrials |
Related Entries
Scaffolds
Side Effects from Label
Side Effects (PT)
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 249296-44-4 |
| ChEMBL | CHEMBL1396 |
| DrugBank | DB01273 |
| FDA SRS | W6HS99O8ZO |
| Guide to Pharmacology | 5459 |
| PubChem | 5310966 |
| SureChEMBL | SCHEMBL225687 |
CONTENTS